Pressure from global pharma forced Ensol Biosciences to show exactly how H1K works. The South Korean biotech now claims it has the answer: a nine-amino-acid peptide that flips its biological role depending on acidity. This pH switch could give H1K an edge in a market crowded with injectable GLP-1 drugs.
In preclinical mouse models, H1K was reported to reduce liver fat accumulation and significantly lower blood cholesterol levels, although detailed experimental data have not been disclosed.
Mechanism validation and oral stability
Microscale thermophoresis protein binding assays and cell-based studies confirmed H1K’s dual-target action. The peptide only activates IGF-1R at pH 3.5, matching stomach acidity, and stays inactive in neutral conditions. H1K also proved tough under digestive stress: it kept over 98% of its structure after 30 minutes at pH 3 and survived three hours with pepsin. That kind of resilience is rare for oral protein drugs and points to real potential for safe absorption through the gut.
Industry publications from October 2026 report that Ensol is in active licensing talks with global pharma and biotech firms over H1K. No licensing deal or regulatory approval has been confirmed publicly. Negotiations had stalled until Ensol could show how H1K works at the molecular level. Last year’s combination therapy data with GLP-1 receptor agonists drew attention, but the missing mechanism kept partners on the sidelines. With that gap closed, Ensol is now leveraging its track record in technology transfer to chase a major licensing agreement.
Addressing GLP-1 limitations and expanding metabolic potential
All currently available results for H1K are from preclinical studies; there is no registration number for a clinical trial, no human trial data, and no regulatory decision or application date for MFDS or FDA approval disclosed in public materials. Thus, efficacy, safety, and oral absorption in humans remain unconfirmed.
Industry sources now expect Ensol’s mechanistic breakthrough to drive a licensing deal that could reach the trillion-won mark. The global obesity drug market is on track to top $100 billion by 2030. Ensol’s earlier licensing wins—P2K (SB-01) for degenerative disc disease and E1K for knee osteoarthritis—add weight to its pitch. The company’s finances got a boost from a recent 5 billion won capital injection led by Hyung In-woo, bringing total backing to 65 billion won. This strengthens Ensol’s hand as it prepares for a transfer listing from KONEX to KOSDAQ.
Market momentum and competitive landscape
GLP-1 drug use is climbing fast. A Gallup survey found U.S. adult use of GLP-1 injectables jumped from 3% in 2024 to 11% this year, with 15% saying they have used them at some point. J.P. Morgan Global Research projects 25 million Americans will be on GLP-1 treatment by 2030. Eli Lilly’s tirzepatide-based drugs pulled in $36.5 billion last year, while Novo Nordisk’s semaglutide franchise made $31 billion. Ensol’s H1K now enters the fray with an oral option, a validated mechanism, and the potential to tackle the rebound problem that dogs current therapies.
Mechanistic clarity has become a key bargaining chip as the obesity drug race heats up. Ensol’s ability to deliver peer-reviewed data on H1K’s pH-dependent dual-target action has revived stalled talks and put the company in the running for a transformative licensing deal. The next step is whether Ensol can turn scientific validation into a commercial contract. Earlier sector reporting, including this analysis, shows how quickly fortunes can shift in the obesity drug battle.
